Opinions
Julien Nono-Womdim
Harrow Inc.
HROW-Q
TOP PICK
Sep 15, 2025
$42.820
Stock price when the opinion was issued
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
It is in the eye care business and focuses on ophthalmology and biotech. One question is how easily can they get drugs to patients. Their first interesting drug is for dry eyes and the second is an anesthetic for surgeries, especially cataract surgery. This one is stable and consistent from patient to patient. Other anesthetics vary in their length of time they are effective from patient to patient. Has stable cash flows from its compounding business and accelerating growth from key products. Could get from under $300 million in revenue today to $1 billion in revenue in the next four years as well as tripling margins. Buy 8 Hold 0 Sell 0
(Analysts’ price target is $59.83)